Peer-reviewed veterinary case report
Immune-mediated anemia in dogs - causes and treatment review
By Piek, Christine J·Published in The veterinary quarterly·2011·Department of Clinical Sciences of Companion Animals, Netherlands·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Canine idiopathic immune-mediated haemolytic anaemia: a review with recommendations for future research.
- Species:
- dog
Plain-English summary
A dog with idiopathic immune-mediated hemolytic anemia (IMHA) can show symptoms like weakness, pale gums, and rapid breathing. This condition occurs when the dog's immune system mistakenly attacks its own red blood cells, leading to severe anemia. Unfortunately, about half of the dogs diagnosed with IMHA may not survive beyond two weeks, and treatments like corticosteroids haven't shown clear benefits when combined with other medications. Ongoing research aims to improve diagnostic tests and treatment strategies, as the current outcomes for dogs with IMHA remain quite poor.
People also search for: dog anemia symptoms · IMHA treatment for dogs · why is my dog weak and pale · immune-mediated hemolytic anemia in dogs · dog blood test results explained
Abstract
Idiopathic immune-mediated haemolytic anaemia (IMHA) is one of the most common immune-mediated diseases of dogs. The aim of this article is to review current knowledge of canine IMHA, its etiology, clinical presentation, diagnosis, complications, and treatment, in an attempt to establish why its outcome is still so poor. Clinical signs of anaemia develop within 3 days and dogs present with a median haematocrit of 13%, leucocytosis, a left shift, and reticulocytosis. Coagulation test results support the presence of disseminated intravascular coagulation. About 50% of dogs die in the first 2 weeks after presentation, and analysis of risk factors suggests that mortality is associated with hypercoagulability, inflammatory response, and liver and kidney failure. A positive direct agglutination test, spherocytosis, and true autoagglutination are widely accepted tests to demonstrate anti-erythrocyte antibodies, but are not yet standardized. To date, there is no evidence to support the efficacy of immunomodulators in addition to corticosteroids in the treatment of IMHA. Despite numerous investigations, the prognosis of IMHA remains dismal. There is an urgent need to validate and standardize diagnostic tests and criteria, and clinical trials might benefit from stratifying dogs by mortality risk. Analysis of samples from well-defined cases of canine IMHA might provide insight into the aetiology and pathophysiology of IMHA.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22029883/